ストックスクリーナーアプリを入手
1.8492
14.80%
0.2292
前日終値:
$1.62
開ける：
$1.74
24時間の取引高:
702.33K
Relative Volume:
2.21
時価総額：
$215.58M
収益：
-
当期純損益:
$-13.73M
株価収益率:
-14.22
EPS:
-0.13
ネットキャッシュフロー:
$-3.92M
1週間 パフォーマンス:
+23.99%
1か月 パフォーマンス:
+19.99%
6か月 パフォーマンス:
+110.15%
1年 パフォーマンス:
+106.62%
1日の値動き範囲:
$1.7388
$1.88
1週間の範囲:
$1.44
$1.88
52週間の値動き範囲:
$0.6295
$1.91
Tiziana Life Sciences Ltd Stock (TLSA) Company Profile
TLSA を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
TLSA
Tiziana Life Sciences Ltd
|
1.845 | 171.77M | 0 | -13.73M | -3.92M | -0.13 |
|
VRTX
Vertex Pharmaceuticals Inc
|
475.91 | 119.21B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
572.20 | 59.16B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
325.99 | 40.57B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
573.25 | 34.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
296.03 | 29.19B | 3.81B | -644.79M | -669.77M | -6.24 |
Tiziana Life Sciences Ltd Stock (TLSA) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2020-12-22 | 開始されました | B. Riley Securities | Buy |
| 2018-12-17 | 開始されました | Laidlaw | Buy |
Tiziana Life Sciences Ltd (TLSA) 最新ニュース
Is Tiziana Life Sciences Ltd a good long term investmentAccelerated wealth expansion - jammulinksnews.com
Tiziana Life Sciences Ltd Stock Analysis and ForecastDynamic investment growth - jammulinksnews.com
What analysts say about Tiziana Life Sciences Ltd stockRapid wealth accumulation - jammulinksnews.com
Promising Penny Stocks To Watch In July 2025 - Yahoo Finance
Tiziana Life Sciences stock initiated with Buy rating at Lucid Capital Markets - Investing.com Australia
Tiziana Life Sciences (TLSA) Receives Buy Rating with Promising Outlook | TLSA Stock News - GuruFocus
What drives Tiziana Life Sciences Ltd stock priceRapid market gains - jammulinksnews.com
Tiziana Life Sciences reports encouraging results from nasal Alzheimer’s treatment - Proactive financial news
Breakthrough: New Alzheimer's Drug Shows Unexpected Dual ActionFights Inflammation and Amyloid Plaques - Stock Titan
Will Tiziana Life Sciences Ltd stock benefit from interest rate changesFree Predictions - beatles.ru
Is Tiziana Life Sciences Ltd stock a growth or value playFree Financial Group - Newser
What analysts say about Tiziana Life Sciences Ltd stock outlookFree Risk Assessment Services - Newser
Why Tiziana Life Sciences Ltd stock is on top investor watchlistsFree Access to Investment Community - Newser
How Tiziana Life Sciences Ltd stock performs during market volatilityROI Driven Alerts - Newser
What makes Tiziana Life Sciences Ltd stock price move sharplySteady Profit Stock Forecasts - Newser
Why Tiziana Life Sciences Ltd stock attracts strong analyst attentionFree Access to Investors Club - Newser
Multiple Sclerosis Pipeline Landscape Appears Robust With 75+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight - The Globe and Mail
Tiziana Life Sciences Ltd (TLSA) Stock: A Year of Stock Market Ups and Downs - investchronicle.com
Promising Penny Stocks To Consider In June 2025 - simplywall.st
Tiziana: Scope Of Foralumab Goes Beyond That Of Multiple Sclerosis Targeting (NASDAQ:TLSA) - Seeking Alpha
Tiziana Life Sciences Adds Fifth Site for Phase 2 Foralumab Trial in Multiple Sclerosis - MarketScreener
Small cap wrap: Tiziana Life Sciences, Challenger Energy, Arrow Exploration... - Proactive financial news
Tiziana expands Phase 2 MS trial to fifth site, commences patient dosing - Proactive financial news
Tiziana Life Sciences Expands Phase 2 Clinical Trial of Intranasal Foralumab with Commencement of First Patient Dosing at Weill Cornell Multiple Sclerosis Center - The Manila Times
Breakthrough Multiple Sclerosis Treatment Enters Next Phase as Weill Cornell Joins Major Clinical Trial - Stock Titan
Market movers: RH, Tiziana, Archer Aviation... - Proactive Investors
Shares of Tiziana Life Sciences (TLSA) Climb on CEO's Upcoming P - GuruFocus
Tiziana shares rise on presentation date for foralumab data - Seeking Alpha
Tiziana CEO to present clinical advances of intranasal foralumab at BIO 2025 - Proactive financial news
Tiziana Life Sciences to Present at the Bio International Convention - The Manila Times
Revolutionary Intranasal Treatment for MS and Alzheimer's: Tiziana CEO Reveals Latest Clinical Findings at BIO 2025 - Stock Titan
Tiziana Life Sciences Ltd (TLSA) Stock: A Comprehensive 52-Week Review - investchronicle.com
Tiziana Life Sciences (NASDAQ:TLSA) Stock Price Up 15.3% – Still a Buy? - Defense World
Tiziana Life Sciences Ltd (TLSA) 財務データ
収益
当期純利益
現金流量
EPS
4.15%
0.50%
大文字化:
|
ボリューム (24 時間):